


## Propiverine hydrochloride

<b>Cat. No.:</b>	HY-116408A
<b>CAS No.:</b>	54556-98-8
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>30</sub> ClNO <sub>3</sub>
<b>Molecular Weight:</b>	403.94
<b>Target:</b>	mAChR; Calcium Channel
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (123.78 mM; Need ultrasonic)  
H<sub>2</sub>O : 50 mg/mL (123.78 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.4756 mL	12.3781 mL	24.7562 mL
	5 mM	0.4951 mL	2.4756 mL	4.9512 mL
	10 mM	0.2476 mL	1.2378 mL	2.4756 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 100 mg/mL (247.56 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (6.19 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (6.19 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (6.19 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties. Propiverine hydrochloride can be used for the research of overactive bladder and urinary incontinence<sup>[1][2]</sup>.

#### In Vitro

Propiverine (10-3000 nM) inhibits the specific binding of [<sup>3</sup>H]NMS, with K<sub>i</sub>s of 339, 193 and 497 nM in the bladder, submaxillary gland and heart of mice respectively<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

Propiverine (0.5 mg/day; p.o. once daily for 2 weeks) significantly increases UBP and LPP during passive intravesical pressure elevation, and also increases plasma norepinephrine and epinephrine levels in rats<sup>[1]</sup>.

Propiverine (0.01-1 mg/kg; i.v.) decreases the UBP and totally suppresses the sneeze reflex at the dose of 1 mg/kg in vivo<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female adult Sprague-Dawley rats (250-270 g) <sup>[1]</sup>
Dosage:	5 mg dissolved in distilled water (0.5 mL)
Administration:	P.o. once daily for 2 weeks
Result:	Increased urethral baseline pressure (UBP) and leak-point pressure (LPP) significantly. Increased plasma epinephrine and norepinephrine levels. No significant changes were observed in body weight.

## REFERENCES

[1]. Kitta T, et, al. Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats. Int Urogynecol J. 2013 Apr; 24(4): 683-8.

[2]. Ito Y, et, al. Muscarinic Receptor Binding and Plasma Drug Concentration after the Oral Administration of Propiverine in Mice. Low Urin Tract Symptoms. 2010 Apr; 2(1):43-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA